Financial Ratios Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
Equities
600329
CNE000001808
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 41.12 CNY | +0.15% |
|
+0.05% | -9.86% |
| Mar. 31 | Tianjin Pharmaceutical Da Ren Tang's Attributable Profit Drops 4.4% in 2025 | MT |
| Mar. 31 | Singapore Shares Remain in Red Amid Soaring Energy Costs; Rex International Plunges 20% | MT |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 4.23 | 4.37 | 4.9 | 4.61 | 5.11 | |||||
Return on Total Capital | 5.85 | 6.27 | 7.24 | 6.51 | 7.62 | |||||
Return On Equity % | 12.63 | 13.37 | 14.68 | 30.56 | 28.24 | |||||
Return on Common Equity | 12.64 | 13.38 | 15.04 | 30.87 | 28.52 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 39.76 | 39.49 | 43.66 | 47.94 | 73.31 | |||||
SG&A Margin | 27.94 | 28.45 | 30.5 | 33.65 | 49.15 | |||||
EBITDA Margin % | 10.12 | 9.5 | 11.23 | 12.22 | 20.87 | |||||
EBITA Margin % | 8.59 | 8.21 | 9.96 | 10.82 | 19.02 | |||||
EBIT Margin % | 8.5 | 8.14 | 9.72 | 10.59 | 18.67 | |||||
Income From Continuing Operations Margin % | 11.39 | 10.59 | 11.78 | 30.32 | 42.92 | |||||
Net Income Margin % | 11.13 | 10.45 | 12 | 30.51 | 43.34 | |||||
Net Avail. For Common Margin % | 11.13 | 10.45 | 12 | 30.51 | 43.34 | |||||
Normalized Net Income Margin | 7.37 | 7.38 | 8.76 | 23 | 33.37 | |||||
Levered Free Cash Flow Margin | 2.31 | 11.24 | 4.45 | 24.88 | 42.02 | |||||
Unlevered Free Cash Flow Margin | 2.34 | 11.32 | 4.72 | 25.22 | 42.14 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.8 | 0.86 | 0.81 | 0.7 | 0.44 | |||||
Fixed Assets Turnover | 4.69 | 5.59 | 5.66 | 5.15 | 3.88 | |||||
Receivables Turnover (Average Receivables) | 3.5 | 3.51 | 3.05 | 3.67 | 3.39 | |||||
Inventory Turnover (Average Inventory) | 2.76 | 3.38 | 3.09 | 2.67 | 1.09 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 2.64 | 2.17 | 2.03 | 2.35 | 1.59 | |||||
Quick Ratio | 1.81 | 1.7 | 1.51 | 1.87 | 1.31 | |||||
Operating Cash Flow to Current Liabilities | 0.35 | 0.2 | 0.21 | 0.33 | 0.1 | |||||
Days Sales Outstanding (Average Receivables) | 104.36 | 104.1 | 119.6 | 99.61 | 107.63 | |||||
Days Outstanding Inventory (Average Inventory) | 132.15 | 108.02 | 118.04 | 137.23 | 336.33 | |||||
Average Days Payable Outstanding | 93.24 | 98.72 | 96.89 | 73.28 | 66.56 | |||||
Cash Conversion Cycle (Average Days) | 143.28 | 113.4 | 140.74 | 163.56 | 377.4 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 0.66 | 4.09 | 5.1 | 0.49 | 1.07 | |||||
Total Debt / Total Capital | 0.66 | 3.93 | 4.86 | 0.49 | 1.05 | |||||
LT Debt/Equity | 0.18 | 2.48 | 3.82 | 0.2 | 0.21 | |||||
Long-Term Debt / Total Capital | 0.18 | 2.38 | 3.63 | 0.2 | 0.2 | |||||
Total Liabilities / Total Assets | 28.16 | 35.49 | 35.04 | 27.1 | 39.26 | |||||
EBIT / Interest Expense | 199.87 | 65.38 | 22.29 | 19.26 | 100.17 | |||||
EBITDA / Interest Expense | 238.55 | 76.51 | 25.86 | 22.33 | 112.32 | |||||
(EBITDA - Capex) / Interest Expense | 185.12 | 66 | 21.93 | 19.4 | 99.38 | |||||
Total Debt / EBITDA | 0.06 | 0.34 | 0.37 | 0.04 | 0.07 | |||||
Net Debt / EBITDA | -3.35 | -3.33 | -1.99 | -4.35 | -4.14 | |||||
Total Debt / (EBITDA - Capex) | 0.08 | 0.4 | 0.43 | 0.05 | 0.08 | |||||
Net Debt / (EBITDA - Capex) | -4.32 | -3.86 | -2.35 | -5.01 | -4.67 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 4.6 | 19.42 | -0.33 | -11.14 | -32.7 | |||||
Gross Profit, 1 Yr. Growth % | 6.46 | 18.59 | 10.21 | -2.42 | 2.9 | |||||
EBITDA, 1 Yr. Growth % | 5.82 | 11.78 | 17.48 | -5.75 | 14.61 | |||||
EBITA, 1 Yr. Growth % | 6.08 | 13.78 | 20.51 | -6.16 | 17.91 | |||||
EBIT, 1 Yr. Growth % | 6.53 | 14.36 | 19.06 | -5.72 | 18.58 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 15.77 | 10.98 | 10.93 | 128.68 | -4.72 | |||||
Net Income, 1 Yr. Growth % | 16.24 | 12.05 | 14.49 | 125.94 | -4.41 | |||||
Normalized Net Income, 1 Yr. Growth % | 15.41 | 19.46 | 18.26 | 129.26 | -2.35 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 16.28 | 11 | 15.32 | 125.78 | -4.15 | |||||
Accounts Receivable, 1 Yr. Growth % | -0.01 | 38.26 | -2.62 | -50.38 | 19.37 | |||||
Inventory, 1 Yr. Growth % | 2.51 | -6.27 | 9.59 | -17.93 | -11.88 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 1.83 | -1.46 | -1.58 | -3.33 | -18.08 | |||||
Total Assets, 1 Yr. Growth % | 9.46 | 12.02 | 0.72 | 5.26 | 8.55 | |||||
Tangible Book Value, 1 Yr. Growth % | 10 | -0.17 | 1 | 21.22 | -9.68 | |||||
Common Equity, 1 Yr. Growth % | 9.57 | 2.47 | 1.21 | 18.83 | -9.49 | |||||
Cash From Operations, 1 Yr. Growth % | 26.95 | -20.55 | 1.66 | 34.3 | -50.14 | |||||
Capital Expenditures, 1 Yr. Growth % | -17.03 | -31.25 | 30.61 | -16.4 | 0.68 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -41.09 | 520.52 | -61.95 | 404.39 | 13.69 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -40.41 | 517.23 | -59.89 | 381.42 | 12.45 | |||||
Dividend Per Share, 1 Yr. Growth % | 66.67 | 124 | 14.29 | 0 | 274.22 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | -0.62 | 11.77 | 9.1 | -5.89 | -22.67 | |||||
Gross Profit, 2 Yr. CAGR % | -3.02 | 12.37 | 14.32 | 3.7 | 0.21 | |||||
EBITDA, 2 Yr. CAGR % | 5.75 | 8.91 | 14.76 | 6.59 | 4.07 | |||||
EBITA, 2 Yr. CAGR % | 5.23 | 10.04 | 17.29 | 7.89 | 5.35 | |||||
EBIT, 2 Yr. CAGR % | 5.42 | 10.38 | 16.68 | 7.38 | 5.73 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 11.29 | 13.35 | 10.95 | 59.27 | 47.61 | |||||
Net Income, 2 Yr. CAGR % | 10.88 | 14.12 | 13.26 | 60.84 | 46.96 | |||||
Normalized Net Income, 2 Yr. CAGR % | 7.54 | 17.42 | 18.89 | 66.13 | 49.62 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 11.11 | 13.61 | 13.14 | 61.36 | 47.11 | |||||
Accounts Receivable, 2 Yr. CAGR % | 4.71 | 17.58 | 16.03 | -30.49 | -23.04 | |||||
Inventory, 2 Yr. CAGR % | -2.2 | -1.98 | 1.35 | -5.16 | -14.96 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 4.26 | 0.17 | -1.52 | -2.46 | -11.01 | |||||
Total Assets, 2 Yr. CAGR % | 7.52 | 10.73 | 6.22 | 2.97 | 6.9 | |||||
Tangible Book Value, 2 Yr. CAGR % | 8.75 | 4.79 | 0.41 | 10.65 | 4.64 | |||||
Common Equity, 2 Yr. CAGR % | 8.68 | 5.96 | 1.84 | 9.67 | 3.71 | |||||
Cash From Operations, 2 Yr. CAGR % | 31.16 | 0.43 | -10.13 | 16.85 | -18.17 | |||||
Capital Expenditures, 2 Yr. CAGR % | -12.63 | -24.47 | -5.24 | 4.49 | -8.26 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -33.85 | 85.02 | 56.43 | 37.51 | 139.46 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -33.75 | 85.66 | 60.17 | 38 | 132.67 | |||||
Dividend Per Share, 2 Yr. CAGR % | 29.1 | 93.22 | 60 | 6.9 | 93.45 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 2.8 | 5.66 | 7.58 | 1.89 | -15.84 | |||||
Gross Profit, 3 Yr. CAGR % | 1.59 | 3.71 | 11.64 | 8.45 | 3.44 | |||||
EBITDA, 3 Yr. CAGR % | 10.43 | 7.82 | 11.8 | 8.4 | 9.3 | |||||
EBITA, 3 Yr. CAGR % | 9.7 | 8.12 | 13.55 | 9.94 | 11.25 | |||||
EBIT, 3 Yr. CAGR % | 9.83 | 8.32 | 13.2 | 9.66 | 10.99 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 11.49 | 11.18 | 12.54 | 41.2 | 34.2 | |||||
Net Income, 3 Yr. CAGR % | 11.05 | 11.27 | 14.25 | 42.58 | 35.23 | |||||
Normalized Net Income, 3 Yr. CAGR % | 10.03 | 11.37 | 17.72 | 48.86 | 39.17 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 11.06 | 11.07 | 14.17 | 42.44 | 35.64 | |||||
Accounts Receivable, 3 Yr. CAGR % | 4.91 | 14.88 | 10.42 | -12.58 | -16.76 | |||||
Inventory, 3 Yr. CAGR % | 4.71 | -3.58 | 1.74 | -5.53 | -7.46 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 7.4 | 2.32 | -0.42 | -2.13 | -7.97 | |||||
Total Assets, 3 Yr. CAGR % | 8.47 | 9 | 7.29 | 5.9 | 4.8 | |||||
Tangible Book Value, 3 Yr. CAGR % | 9.06 | 5.69 | 3.51 | 6.92 | 3.41 | |||||
Common Equity, 3 Yr. CAGR % | 8.91 | 6.57 | 4.35 | 7.21 | 2.87 | |||||
Cash From Operations, 3 Yr. CAGR % | 34.52 | 10.98 | 0.84 | 2.75 | -12.03 | |||||
Capital Expenditures, 3 Yr. CAGR % | -3.71 | -19.34 | -9.35 | -9.12 | 3.2 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 25.6 | 36.49 | 10.52 | 129.96 | 29.06 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 22.57 | 36.42 | 12.73 | 130.08 | 28.9 | |||||
Dividend Per Share, 3 Yr. CAGR % | 31.48 | 55.13 | 62.19 | 36.8 | 62.32 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 2.05 | 7.71 | 5.28 | 0.88 | -5.73 | |||||
Gross Profit, 5 Yr. CAGR % | 6.39 | 8.16 | 6.51 | 3.7 | 6.92 | |||||
EBITDA, 5 Yr. CAGR % | 16.15 | 14.19 | 12.2 | 7.39 | 9.2 | |||||
EBITA, 5 Yr. CAGR % | 17.3 | 14.98 | 12.75 | 8.1 | 10.84 | |||||
EBIT, 5 Yr. CAGR % | 17.62 | 15.19 | 12.52 | 7.94 | 10.74 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 13.99 | 13.03 | 11.28 | 28.37 | 25.44 | |||||
Net Income, 5 Yr. CAGR % | 12.67 | 12.6 | 11.93 | 28.94 | 26.35 | |||||
Normalized Net Income, 5 Yr. CAGR % | 12.15 | 12.53 | 13.49 | 30.71 | 30.04 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 12.7 | 12.35 | 11.89 | 28.97 | 26.36 | |||||
Accounts Receivable, 5 Yr. CAGR % | 6.19 | 12.4 | 9.23 | -6.04 | -4.43 | |||||
Inventory, 5 Yr. CAGR % | 10.42 | 5.29 | 3.35 | -4.21 | -5.3 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 8.35 | 6.37 | 3.74 | 0.38 | -4.8 | |||||
Total Assets, 5 Yr. CAGR % | 7.07 | 8.93 | 7.56 | 6.55 | 7.13 | |||||
Tangible Book Value, 5 Yr. CAGR % | 9.02 | 7.45 | 5.52 | 7.64 | 3.96 | |||||
Common Equity, 5 Yr. CAGR % | 8.76 | 7.81 | 6.02 | 7.8 | 4.1 | |||||
Cash From Operations, 5 Yr. CAGR % | 15.33 | 179.47 | 14.48 | 13.29 | -7.24 | |||||
Capital Expenditures, 5 Yr. CAGR % | 5.84 | -1.17 | -4.33 | -10.54 | -8.91 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | -11.77 | 45.51 | 35.33 | 37.88 | 50.13 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | -12.18 | 46.97 | 34.65 | 38.03 | 50.22 | |||||
Dividend Per Share, 5 Yr. CAGR % | 14.87 | 41.14 | 42.22 | 33.66 | 74.04 |
Select your edition
All financial news and data tailored to specific country editions
















